The plasma release of atrial natriuretic peptide in man

Anderson, J. V.; Donckier, Julian; McKenna, William J.; Bloom, Stephen R.

doi:10.1042/cs0710151

Cited by 141 publications

(49 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the finding that significant changes in atrial pressures achieved by the low infusion rate of phenylephrine were not accompanied by an increase in irANF, we would postulate that the increased secretion of ANF has a lag period after a pressure increase of at least 4 minutes and perhaps as much as 15 minutes. Our studies with hemodynamically monitored rapid saline infusions suggest a 2-to 15-minute lag period, 10 and Anderson et al 23 reported a 10-to 30-minute delay using a similar protocol.…”

mentioning

confidence: 92%

Effect of vasopressors on atrial natriuretic factor and hemodynamic function in humans.

et al. 1988

View full text Add to dashboard Cite

mentioning

confidence: 92%

Effect of vasopressors on atrial natriuretic factor and hemodynamic function in humans.

et al. 1988

View full text Add to dashboard Cite

“…ANP is released into the circulation after atrial distension. 9,10 Plasma ANP is considered a prognostic marker for acute heart failure, risk of cardiovascular events, and death. 11,12 Previous studies of ANP in maternal circulation in pregnancy are controversial, with reports of increased, [13][14][15][16] as well as similar, [17][18][19] circulating ANP concentrations in preeclampsia compared with normotensive pregnancy.…”

mentioning

confidence: 99%

Cardiovascular Biomarker Midregional Proatrial Natriuretic Peptide During and After Preeclamptic Pregnancies

et al. 2012

View full text Add to dashboard Cite

Abstract-Preeclampsia is associated with increased risk of cardiovascular disease. Midregional proatrial natriuretic peptide (MR-proANP), a precursor of the atrial natriuretic peptide, is a biomarker for cardiovascular disease. We obtained plasma from 184 pregnant women in gestational weeks 24 to 42 (normotensive pregnancies: nϭ77, preeclampsia: nϭ107), from 25 of these women at 5 to 8 years after index pregnancy (normotensive pregnancies: nϭ11, preeclampsia: nϭ14), and from 49 normotensive, nonpregnant women and analyzed them by immunoassay for MR-proANP. To investigate potential sources, placental and decidual atrial natriuretic peptide mRNA expression levels were analyzed by quantitative real-time PCR in 21 normotensive and 23 preeclamptic pregnancies, as well as in human heart and kidney samples. For further confirmation, we measured circulating MR-proANP and performed expression studies in a transgenic rat model for preeclampsia. MR-proANP was significantly elevated in maternal plasma in preeclampsia compared with normotensive pregnancies (135 versus 56 pmol/L; PϽ0.001). However, 5 to 8 years after pregnancy, there was no difference (formerly preeclamptic women versus formerly normotensive in pregnancy: 53 versus 49 pmol/L; Pϭ0.5). Our preeclamptic rat model confirmed the acute MR-proANP differences between preeclamptic and normotensive pregnancies (10.9Ϯ1.9 versus 4.3Ϯ0.3 pmol/L; Pϭ0.05). Atrial natriuretic peptide expression was high in the heart but negligible in the uteroplacental unit in both normotensive humans and rats, whereas expression in maternal and fetal hearts in the preeclamptic rats was significantly increased, compared with controls. MR-proANP is a serviceable biomarker in preeclampsia, both in humans and a rat model, probably reflecting cardiovascular hemodynamic stress. Key Words: biological marker Ⅲ cardiovascular disease Ⅲ midregional proatrial natriuretic peptide Ⅲ preeclampsia Ⅲ pregnancy Ⅲ postpartum Ⅲ transgenic rats P reeclampsia, defined as the development of de novo hypertension and proteinuria after 20 weeks of gestation, affects 3% to 5% of all pregnancies. 1 The pathophysiology of preeclampsia remains unknown; however, dysregulated immunologic factors are proposed to underlie a defective placentation and reduced remodeling of maternal uteroplacental spiral arteries by fetal trophoblasts. 2 These mechanisms are suggested to result in an oxidatively stressed placenta that produces circulating factors causing an excessive systemic inflammatory response and generalized maternal endothelial dysfunction. 3,4 Preeclampsia and cardiovascular disease share many risk factors. 5,6 Women with preeclampsia have increased cardiovascular morbidity and mortality later in life. 7,8 Atrial natriuretic peptide (ANP) is a diuretic, natriuretic, and vasodilatory cardiac hormone. ANP is released into the circulation after atrial distension. 9,10 Plasma ANP is considered a prognostic marker for acute heart failure, risk of cardiovascular events, and death. 11,12 Previous studies of ANP in maternal c...

show abstract

“…Mean venous plasma IR-ANP concentration in resting adult subjects, consuming a normal diet, range from approximately 5 to 20 pmol/l (1 5-60 pg/ml) according to most published methods (Arendt et al, 1985;Yamaji et al, 1985b;Anderson et a[., 1986d;Weidmann et al, 1986a;Yandle et al, 1986b). Plasma levels may be higher in the elderly (Ohashi et al, 1986) but the effect of age and sex requires further study.…”

Section: Normal Subjectsmentioning

confidence: 99%

“…Since the metabolic clearance rate of IR-ANP is unaffected by major variations in sodium intake (Cuneo et al, 1986), these changes in plasma IR-ANP levels must be due to alterations in cardiac secretion of the peptide. Other manoeuvres causing central blood volume expansion such as intravenous saline loads (Sagnella et al, 1985;Yamaji et a!., 1985b;Anderson et al, 1986d) head out water immersion (Epstein et al, 1986) and head down tilting (Hodsman et al, 1985) also increase plasma IR-ANP. Presumably for the same reasons, plasma levels increase when subjects change posture from erect to supine position .…”

Section: Normal Subjectsmentioning

confidence: 99%